Chemosensitivity-related genes of breast cancer detected by DNA microarray.
BACKGROUND
The feasibility of a preoperative docetaxel/5'-deoxy-5-fluorouridine (5'-DFUR) regimen for breast cancer patients was examined and the genes related to the response to it was investigated.


METHODS
Women with advanced breast cancer were treated with docetaxel (60 mg/m2, day 1) and 5'-DFUR (800 mg/day, on days 1-14) q3 weeks by 4 cycles. Microarray analysis was carried out using preoperative core biopsy samples. Based on the mRNA expression levels, genes related to clinical and pathological responses were selected.


RESULTS
The docetaxel/5'-DFUR regimen showed a 86% clinical response rate including 42% complete response, one pathological complete response and one ductal carcinoma in situ component. In microarray analysis, we identified 6 genes, including IGF-1, and derived a predictive formula with 67% accuracy. In addition, x2 analysis revealed a tendency for good response in ER-negative and Her2/neu-positive cases.


CONCLUSIONS
Microarray analysis enabled us to predict the pathological response to docetaxel/5'-DFUR chemotherapy.
Ikeda
Tadashi
T
Department of Surgery, Keio University School of Medicine, Tokyo, Japan. ikedat@med.teikyo-u.ac.jp
Jinno
Hiromitsu
H
Shirane
Masatoshi
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D000077143:Docetaxel; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D020869:Gene Expression Profiling; D006801:Humans; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D011237:Predictive Value of Tests; D043823:Taxoids / Q000008:administration & dosage
D043823:Taxoids; D005467:Floxuridine; D000077143:Docetaxel; C025034:doxifluridine